Dapagliflozin plus exenatide on patients with type 2 diabetes awaiting bariatric surgery in the DEXBASU study.

López-Cano C, Santos MD, Sánchez E, Martí R, Bueno M, Gutiérrez-Carrasquilla L, Lecube A

Scientific reports25 Feb 2022Cited by 5 (Europe PMC)

PMID35217772PMCIDPMC8881618DOI10.1038/s41598-022-07250-zPepBankPUB-35217772

Summary

The glucagon-like peptide-1 receptor agonist family together with the renal sodium/glucose cotransporter-2 inhibitors have garnered interest as potential therapeutic agents for subjects with type 2 diabetes and obesity. In these patients, bariatric surgery is indicated based in a BMI ≥ 35 kg/m². A 24-week non-blinded, randomized pilot study to assess the efficacy of subcutaneous exenatide 2.0 mg once weekly plus oral dapagliflozin 10 mg once daily (Group A) compared to a control group (Group B) in 56 patients with type 2 diabetes awaiting bariatric surgery was conducted (EudraCTid.: 2017-001,454-33). Both groups received an energy-deficit low-fat diet. The primary endpoint was the proportion of patients running off the criteria for bariatric surgery at the end of the follow-up period (BMI ≤ 35.0 kg/m² or a BMI ≤ 40.0 kg/m² plus an HbA1c ≤ 6.0%). Changes in the BMI were also of interest. The proportion of patients who ran off the criteria for bariatric surgery was larger in Group A than in the control group (45.8% vs. 12.0%, p = 0.010). Participants in Group A exhibited an absolute decrease in body weight and BMI of 8.1 kg (95%IC: - 11.0 to - 5.2) and 3.3 kg/m² (95%IC: - 4.5 to - 2.2), respectively (p < 0.001 for both in comparison with Group B). A higher percentage of participants in Group A reached a BMI 2 (45.8 vs 12.0%) and lost > 10% of their initial body weight (20.8 vs 0%) compared to Group B. The combination of exenatide plus dapagliflozin appears as a strategic option to reduce the waiting list for bariatric surgery, especially in those patients with type 2 diabetes.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study5

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone5

In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Exenatide (exendin-4).

01HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialEfficacy outcome
In patients with diabetes awaiting bariatric surgery, exenatide-dapagliflozin increased the proportion no longer meeting surgery criteria versus control.
In plain wordsIn patients with diabetes awaiting bariatric surgery, exenatide-dapagliflozin increased the proportion no longer meeting surgery criteria versus control.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseNo longer meeting bariatric surgery criteria
Study
n = 56
Comparator
Control group receiving an energy-deficit low-fat diet
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Measurements
No longer meeting surgery criteria
45.8%
combination
No longer meeting surgery criteria
12%
control
Source sentences
Summary
The proportion of patients who ran off the criteria for bariatric surgery was larger in Group A than in the control group (45.8% vs. 12.0%, p = 0.010).
2 context sentences(design, population, supporting numbers)
Summary · context
A 24-week non-blinded, randomized pilot study to assess the efficacy of subcutaneous exenatide 2.0 mg once weekly plus oral dapagliflozin 10 mg once daily (Group A) compared to a control group (Group B) in 56 patients with type 2 diabetes awaiting bariatric surgery was conducted (EudraCTid.: 2017-001,454-33).
Summary · context
Both groups received an energy-deficit low-fat diet.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Show in the study text Report a problemFND-3521777201
02HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialEfficacy outcome
In patients with diabetes awaiting bariatric surgery, exenatide-dapagliflozin reduced body weight more than control.
In plain wordsIn patients with diabetes awaiting bariatric surgery, exenatide-dapagliflozin reduced body weight more than control.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseBody weight
Study
n = 56
Comparator
Control group receiving an energy-deficit low-fat diet
Outcome group
Body weight · Metabolic and weight
Measurements
Absolute body weight decrease from baseline, Group A
8.1 kg
combination (Group A) vs Group B
95% CI of body weight change, Group A
−11 to −5.2 kg
combination (Group A)
Source sentences
Summary
Participants in Group A exhibited an absolute decrease in body weight and BMI of 8.1 kg (95%IC: - 11.0 to - 5.2) and 3.3 kg/m² (95%IC: - 4.5 to - 2.2), respectively (p < 0.001 for both in comparison with Group B).
2 context sentences(design, population, supporting numbers)
Summary · context
A 24-week non-blinded, randomized pilot study to assess the efficacy of subcutaneous exenatide 2.0 mg once weekly plus oral dapagliflozin 10 mg once daily (Group A) compared to a control group (Group B) in 56 patients with type 2 diabetes awaiting bariatric surgery was conducted (EudraCTid.: 2017-001,454-33).
Summary · context
Both groups received an energy-deficit low-fat diet.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Show in the study text Report a problemFND-3521777202
03HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialEfficacy outcome
In patients with diabetes awaiting bariatric surgery, exenatide-dapagliflozin reduced BMI more than control.
In plain wordsIn patients with diabetes awaiting bariatric surgery, exenatide-dapagliflozin reduced BMI more than control.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseBMI
Study
n = 56
Comparator
Control group receiving an energy-deficit low-fat diet
Outcome group
Body weight · Metabolic and weight
Measurements
Absolute BMI decrease from baseline, Group A
3.3 kg/m2
combination (Group A) vs Group B
95% CI of BMI change, Group A
−4.5 to −2.2 kg/m2
combination (Group A)
Source sentences
Summary
Participants in Group A exhibited an absolute decrease in body weight and BMI of 8.1 kg (95%IC: - 11.0 to - 5.2) and 3.3 kg/m² (95%IC: - 4.5 to - 2.2), respectively (p < 0.001 for both in comparison with Group B).
2 context sentences(design, population, supporting numbers)
Summary · context
A 24-week non-blinded, randomized pilot study to assess the efficacy of subcutaneous exenatide 2.0 mg once weekly plus oral dapagliflozin 10 mg once daily (Group A) compared to a control group (Group B) in 56 patients with type 2 diabetes awaiting bariatric surgery was conducted (EudraCTid.: 2017-001,454-33).
Summary · context
Both groups received an energy-deficit low-fat diet.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Show in the study text Report a problemFND-3521777203
04HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialEfficacy outcome
In patients with diabetes awaiting bariatric surgery, exenatide-dapagliflozin increased attainment of BMI below 35 versus control.
In plain wordsIn patients with diabetes awaiting bariatric surgery, exenatide-dapagliflozin increased attainment of BMI below 35 versus control.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseBMI below 35
Study
n = 56
Comparator
Control group receiving an energy-deficit low-fat diet
Outcome group
Body weight · Metabolic and weight
Measurements
Reached BMI <35 kg/m2
45.8%
combination (Group A)
Reached BMI <35 kg/m2
12%
control (Group B)
Source sentences
Summary
A higher percentage of participants in Group A reached a BMI 2 (45.8 vs 12.0%) and lost > 10% of their initial body weight (20.8 vs 0%) compared to Group B.
2 context sentences(design, population, supporting numbers)
Summary · context
A 24-week non-blinded, randomized pilot study to assess the efficacy of subcutaneous exenatide 2.0 mg once weekly plus oral dapagliflozin 10 mg once daily (Group A) compared to a control group (Group B) in 56 patients with type 2 diabetes awaiting bariatric surgery was conducted (EudraCTid.: 2017-001,454-33).
Summary · context
Both groups received an energy-deficit low-fat diet.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Show in the study text Report a problemFND-3521777204
05HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialEfficacy outcome
In patients with diabetes awaiting bariatric surgery, exenatide-dapagliflozin increased attainment of weight loss above 10% versus control.
In plain wordsIn patients with diabetes awaiting bariatric surgery, exenatide-dapagliflozin increased attainment of weight loss above 10% versus control.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseWeight loss above 10%
Study
n = 56
Comparator
Control group receiving an energy-deficit low-fat diet
Outcome group
Body weight · Metabolic and weight
Measurements
Lost >10% of initial body weight
20.8%
combination (Group A)
Lost >10% of initial body weight
0%
control (Group B)
Source sentences
Summary
A higher percentage of participants in Group A reached a BMI 2 (45.8 vs 12.0%) and lost > 10% of their initial body weight (20.8 vs 0%) compared to Group B.
2 context sentences(design, population, supporting numbers)
Summary · context
A 24-week non-blinded, randomized pilot study to assess the efficacy of subcutaneous exenatide 2.0 mg once weekly plus oral dapagliflozin 10 mg once daily (Group A) compared to a control group (Group B) in 56 patients with type 2 diabetes awaiting bariatric surgery was conducted (EudraCTid.: 2017-001,454-33).
Summary · context
Both groups received an energy-deficit low-fat diet.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Show in the study text Report a problemFND-3521777205

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.